Start here if you're new
what it is
It makes tools that help doctors steer devices and therapies into the brain and spine.
how it gets paid
Last year Clpt made $31M in revenue. ClearPoint system hardware was the main engine at $12M, or 39% of sales.
what just happened
Revenue reached $27M in the latest quarter, and EPS was -$0.63.
At a glance
B balance sheet — gets the job done, barely
70/100 earnings predictability — reasonably predictable
-$0.70 fy2024 eps est
$2B fy2026 rev est
62.9% operating margin
xvary composite: 49/100 — below average
What they do
It makes tools that help doctors steer devices and therapies into the brain and spine.
ClearPoint sells the navigation system and the disposable parts that go with it. That means one installed setup can keep pulling revenue from repeat procedures. Gross margin → profit after direct costs → so what: 61.3% last quarter, so each $1 of sales kept $0.61 before overhead. Your workflow gets tied to one system, and leaving means retraining the room.
How they make money
$31M
annual revenue
ClearPoint system hardware
$12M
up
Disposable components
$9M
up
Software
$2M
flat
Pre-clinical development services
$5M
up
Clinical and research services
$3M
up
The products that matter
surgical guidance hardware
ClearPoint Navigation System
$12.4M · 40% of revenue
it is the capital equipment layer of the model, generating roughly $12.4M last year. This gets the system into the room, but it is not the growth engine right now.
installed base
procedure-linked recurring revenue
Disposables & Services
$18.6M · +23% growth
this $18.6M segment grew 23% and now carries most of the revenue story. If you are buying CLPT, this is the part you need to keep compounding.
60% of revenue
therapy-enabling workflow expansion
PRISM 1.5T and CRO facility
no revenue breakout disclosed here
management is leaning on these newer initiatives as part of the next growth leg. The current snapshot does not give a revenue contribution yet, which tells you this is still more promise than proof.
future bet
Key numbers
$31M
trailing revenue
This is the current business size. It is tiny next to a $321M market cap and a $2B 2026 estimate.
$2B
fy2026 revenue
This estimate is the whole story. It implies the market is betting on a business many times larger than today.
61.3%
gross margin
This is the money left after direct costs. It tells you the product mix still has some muscle.
62.9%
operating margin
This is the ugly part. The company is still spending far more than it keeps.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $35M (10% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for CLPT right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue reached $27M in the latest quarter, and EPS was -$0.63.
Revenue was up 200% vs. prior year, and gross margin hit 61.3%. The catch is that EPS stayed deeply negative.
$8M
revenue
$0.63
eps
61.3%
gross margin
the number that mattered
Revenue was the number that mattered because $27M shows demand is real, even while losses are still large.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The top risk here is failing to bridge the gap between $31M in trailing revenue and the $56M 2026 consensus. This is not a mature business being graded on steady execution. It is a small medtech being graded on acceleration.
med
2026 consensus is carrying a lot of weight
Analysts are looking for $56M in 2026 revenue against a current $31M base. After three consecutive misses, that target is no longer something you assume — it is something management has to prove.
If formal guidance lands below that level, the stock loses the growth narrative that justifies today's valuation.
med
Good gross margins are being buried by overhead
A 61.3% gross margin would look attractive in many small medtech names. CLPT still posts a -62.9% operating margin. That tells you sales, R&D, and infrastructure are arriving much faster than scale benefits.
If revenue grows without operating leverage, you get a bigger business that still does not earn money.
med
The recurring segment has to keep doing the heavy lifting
Disposables & Services generated $18.6M and grew 23%, while Capital Equipment was flat at $12.4M. That is encouraging, but it also concentrates the investment case into one part of the model.
If procedure-linked revenue slows, the company is left with a flatter hardware business and a much harder path to the 2026 number.
This is a $10.79 stock with a $9–$30 trading range and a story built on future scale. The risk is not subtle: if growth slips, there is not a profitable base business here to hide behind.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
Q4 and FY 2025 earnings on march 17, 2026
This is where management has to put numbers behind the story. The key question is simple: does 2026 guidance support the $56M consensus, or not.
growth
Disposables and services versus capital equipment
You want to see the $18.6M recurring segment keep outgrowing the $12.4M equipment segment. Same company. Very different implications.
sentiment
Analyst revisions after the next print
Recent price targets moved from $28 to $18. Analysts often follow the stock, but estimate cuts still matter when the valuation depends on future revenue.
market access
EU MDR certification translating into commercial traction
The January 2026 software certification cleared a regulatory hurdle. The next step is seeing whether access becomes revenue, because approvals do not book sales on their own.
Analyst rankings
earnings predictability
70 / 100
in human-speak, analysts think this name is somewhat modelable, but not smooth. Three straight forecast misses tell you the range of outcomes is still wide.
risk profile
3
risk rank 3 means this is not an outright distress story, but it is nowhere close to defensive. You own execution risk with extra volatility attached.
source: institutional data
Institutional activity
institutional ownership data for CLPT is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$11
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive